Crescita Therapeutics (CTX) Planet MicroCap Showcase: VANCOUVER 2024 summary

Company overview and market positioning

• Operates as a fully integrated dermatology and skincare company with in-house R&D, manufacturing, and sales teams.

• Portfolio spans aesthetic skincare, medical aesthetics, and a lead prescription product, Pliaglis.

• Manufactures products in a 50,000 sq ft facility in Laval, with significant excess capacity used for third-party production.

• Sells through 1,400 locations across Canada, primarily B2B to spas, medispas, and physician-operated clinics.

• Market cap of CAD 12 million, 2022 revenue of CAD 17.5 million, and CAD 9.1 million in cash as of June 30.

Business segments and financial profile

• Three segments: commercial skincare, manufacturing/services, and licensing.

• Skincare segment provides recurring revenue, representing 40%-60% of total revenue.

• Manufacturing revenue is purchase order-based and variable, with recent efforts to secure long-term contracts.

• Licensing segment centers on Pliaglis, licensed in 39 countries, with launches in Europe, Middle East, and pending in China.

• Focus on increasing recurring revenue and achieving sustainable profitability by 2025-2026.

Recent developments and growth strategies

• Acquired Aquafolia, adding 120 clinics and CAD 1.5 million in revenue, fully integrated into operations.

• Signed a four-year, $2.5 million production agreement and a five-year contract with a healthcare provider, potentially adding CAD 6 million in production.

• Expanding product portfolio through in-house innovation and licensing, including a new Microinjector device.

• Actively seeking a new U.S. partner for Pliaglis after contract termination with Taro Pharmaceuticals.

• M&A remains a key pillar, with disciplined focus on profitability and sustainable revenue.